| Literature DB >> 30622452 |
Tao Wu1,2,3, Jinling Xu1, Yijun Chen2, Rui Liu2, Min Zhang1,2,3.
Abstract
BACKGROUND: Several studies have evaluated the effects of oolong tea extracts on obesity. However, only few studies focused on the anti-obesity effect of specific components of oolong tea.Entities:
Keywords: anti-obesity; oolong tea; polyphenols; polysaccharide
Year: 2018 PMID: 30622452 PMCID: PMC6303733 DOI: 10.29219/fnr.v62.1599
Source DB: PubMed Journal: Food Nutr Res ISSN: 1654-661X Impact factor: 3.894
Body weight and other characters of rats in each group
| Groups | Initial BW(g) | Final BW(g) | Lee’s index | Food utilization (%) |
|---|---|---|---|---|
| NC | 228.58 ± 14.03 | 459.31 ± 27.19 | 311.21 ± 11.83 | 18.73% ± 2.02% |
| MC | 348.74 ± 22.35 | 548.74 ± 51.74 | 339.55 ± 8.06 | 26.87% ± 0.98% |
| OC | 351.33 ± 17.90 | 511.86 ± 43.54 | 322.31 ± 9.66 | 24.35% ± 1.76% |
| TWH | 346.51 ± 19.37 | 466.78 ± 34.21 | 316.08 ± 9.64 | 19.78% ± 2.16% |
| TWL | 352.16 ± 21.12 | 478.61 ± 45.36 | 318.45 ± 12.83 | 20.56% ± 2.29% |
| TPPH | 348.44 ± 16.09 | 473.26 ± 32.75 | 315.34 ± 5.85 | 20.37% ± 3.12% |
| TPPL | 347.89 ± 13.16 | 485.57 ± 34.27 | 324.27 ± 9.03 | 21.51% ± 2.29% |
| TPSH | 349.89 ± 18.27 | 522.72 ± 42.43 | 328.56 ± 5.68 | 22.67% ± 2.03% |
| TPSL | 343.06 ± 16.62 | 505.92 ± 32.48 | 325.73 ± 7.79 | 21.67% ± 1.97% |
| TPSM | 345.73 ± 12.75 | 447.67 ± 33.80 | 318.49 ± 10.14 | 19.04% ± 2.14% |
All values are means ± SD (n = 10). Values with different superscripts are significantly different among the groups by ANOVA with Duncan’s multiple range test from NC at * P < 0.05,
P < 0.01; MC at
P < 0.05,
P < 0.01; OC,
P < 0.05,
P < 0.01.
Fig. 1The effect of oolong tea extracts on rat hepatic lipid profile and antioxidants. (a) Hepatic contents of TG and TC. (b) Hepatic contents of TG and TC. (c) Hepatic MDA content. (d) Hepatic total SOD content. Values with different superscripts are significantly different among the groups by ANOVA with Duncan's multiple range test from NC at *P < 0.05, **P < 0.01; MC at #P < 0.05, ##P < 0.01; OC, &P < 0.05, &&P < 0.01.
Serum figures of rats in each group
| Groups | TC (mmol/) | TG (mmol/L) | HDLC (mmol/L) | LDLC (mmol/L) | MDA (mmol/L) | T-SOD (U/mL) | LEP (pg/mL) |
|---|---|---|---|---|---|---|---|
| NC | 1.57 ± 0.25 | 0.86 ± 0.42 | 2.22 ± 1.64 | 0.94 ± 0.23 | 0.12 ± 0.09 | 157.03 ± 20.24 | 179.73 ± 12.12 |
| MC | 2.58 ± 0.43 | 1.23 ± 0.26 | 1.14 ± 0.16 | 1.52 ± 0.56 | 0.27 ± 0.03 | 122.99 ± 17.16 | 198.82 ± 27.41 |
| OC | 1.56 ± 0.32 | 0.76 ± 0.26 | 1.71 ± 0.55 | 0.40 ± 0.48 | 0.21 ± 0.15 | 184.48 ± 15.27 | 178.82 ± 25.42 |
| TWH | 1.99 ±0.43 | 0.61 ± 0.28 | 1.98 ± 0.53 | 0.91 ± 0.31 | 0.15 ± 0.07 | 187.06 ± 18.00 | 182.91 ± 22.67 |
| TWL | 1.80 ± 0.77 | 0.64 ± 0.33 | 1.74 ± 0.42 | 0.67 ± 0.78 | 0.13 ± 0.07 | 154.45 ± 18.70 | 185.64 ± 29.16 |
| TPPH | 1.97 ± 0.41 | 0.77 ± 0.20 | 2.26 ± 0.40 | 0.73 ± 0.46 | 0.17 ± 0.08 | 97.82 ± 24.34 | 175.18 ± 19.78 |
| TPPL | 1.75 ± 0.48 | 0.68 ± 0.16 | 1.75 ± 0.43 | 0.43 ± 0.64 | 0.10 ± 0.04 | 163.03 ± 18.09 | 178.67 ± 21.07 |
| TPSH | 1.86 ± 0.43 | 1.11 ± 0.34 | 1.65 ± 0.31 | 0.67 ± 0.34 | 0.17 ± 0.11 | 174.83 ± 23.80 | 179.86 ± 16.80 |
| TPSL | 1.58 ± 0.27 | 1.22 ± 0.53 | 1.41 ± 0.34 | 0.36 ± 0.78 | 0.21 ± 0.11 | 192.21 ± 11.58 | 166.50 ± 15.71 |
| TPSM | 1.55 ± 0.25 | 0.69 ± 0.31 | 1.73 ± 0.58 | 0.27 ± 0.43 | 0.13 ± 0.04 | 146.94 ± 19.69 | 170.50 ± 19.16 |
All values are means ± SD (n = 10). Values with different superscripts are significantly different among the groups by ANOVA with Duncan’s multiple range test from NC at
P < 0.05,
P < 0.01; MC at
P < 0.05,
P < 0.01; OC,
P < 0.05,
P < 0.01.
Co-expression of regulated genes related to lipid metabolism
| Tissue | Probe set | Gene symbol | Gene title | RefSeq transcript ID | Levels |
|---|---|---|---|---|---|
|
| 1367667_at | Fdps | Farnesyl diphosphate synthase | NM_031840 | down |
| 1367707_at | Fasn | fatty acid synthase | NM_017332 | down | |
| 1387006_at | Sult2al1 | Sulfotransferase family 2A, dehydroepiandrosterone (DHEA)-preferring-like 1 | NM_012695 | down | |
| 1370281_at | Fabp5 | Fatty acid binding protein 5, epidermal | NM_145878 | down | |
| 1370355_at | Scd1 | Stearoyl-coenzyme A desaturase 1 | NM_139192 | down | |
| 1387123_at | Cyp17a1 | Cytochrome P450, family 17, subfamily a, polypeptide 1 | NM_012753 | down | |
| 1387156_at | Hsd17b2 | Hydroxysteroid (17-beta) Dehydrogenase 2 | NM_024391 | down | |
| 1370566_at | Rdh2 | Retinol dehydrogenase 2 | NM_199208 | down | |
| 1374914_at | Ppard | Peroxisome proliferator-activated receptor delta | XM_001078083 /// | down | |
| 1380013_at | Pnpla3Patatin-like phospholipase domain containing 3 | XM_343302 | up | ||
| 1388108_at | Elovl6 | ELOVL family member 6, elongation of long chain fatty acids (yeast) | NM_134383 /// XM_001075165 | up | |
| 1369179_a_at | Pparg | Peroxisome proliferator-activated receptor gamma | NM_001145366 /// NM_001145367 /// NM_013124 | down | |
| 1367585_a_at | Atplal | ATPase, Na+/K+ transporting, alpha 1 polypeptide | NM_012504 | down | |
| 1367609_at | Mif | Macrophage migration inhibitory factor | NM_031051 | down | |
| 1367894_at | Insig1 | Insulin induced gene 1 | NM_022392 | down | |
| 1370862_at | Apoe | Apolipoprotein E | J02583 | down | |
| 1371691_at | Rarres2 | Retinoic acid receptor responder (tazarotene induced) 2 | BI282993 | down | |
| 1371963_at | Pcca | Propionyl-coenzyme A carboxylase, alpha polypeptide | BF395042 | down | |
| 1375034_at | Pla2g15 | Phospholipase A2, group XV | AI410383 | up | |
| 1387132_at | Lipe | Lipase, hormone sensitive | NM_012859 | up | |
| 1387365_at | Nr1h3 | Nuclear receptor subfamily 1, group H, member 3 | NM_031627 | up | |
| 1379075_at | Mboat2 | Membrane-bound O-acyltransferase domain containing 2 | AI501287 | up | |
| 1382680_at | Adfp | Adipose differentiation-related protein | BG673602 | up | |
| 1386960_at | Slc37a4 | Solute carrier family 37 (glucose-6-phosphate transporter), member 4 | NM_031589 | up |